stockrowKorro Bio, Inc.
KRROKorro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024.
- Revenue
- −86.3%
- EPS
- +61.0%
- Free cash flow
- +12.1%
Quarter to June 2026, against a year earlier
Follow KRRO
Alert me
Korro Bio, Inc. (KRRO) EV/Sales
As of 6 November 2026, Korro Bio, Inc. (KRRO) trades at a EV/Sales of 25.5×. Over the past ten years it has ranged from −2.4× (January 2024) to 42.4× (February 2021); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | (56.14%) |
| FY2024 | 6.6× | 283.19% |
| FY2021 | 1.7× | (93.19%) |
| FY2020 | 25.2× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 2.9× | (88.86%) |
| Sep 2025 | 25.9× | 1,091.33% |
| Jun 2025 | 2.2× | (13.56%) |
| Mar 2025 | 2.5× | (53.06%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | 0.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.1× |
| ACIU AC Immune compare | 9.1× |
| FATE Fate Therapeutics, Inc. compare | 14.0× |
| KRRO Korro Bio, Inc. | 25.5× |
| SLGL Sol-Gel Technologies Ltd. compare | 121× |
| IMRX Immuneering Corporation compare | 293× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)